SCHEMBL3488807

SCHEMBL3488807

Nc1ccc(Oc2ccc(F)c(F)c2)cc1CNC(=O)O

nearest known ligand 0.45

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SLC1A3 P43003 1/20 0.45
SLC1A2 P43004 1/20 0.45
SLC1A1 P43005 1/20 0.45
CARM1 Q86X55 1/20 0.45
PRMT6 Q96LA8 1/20 0.45
SOS1 Q07889 1/20 0.41
KLKB1 P03952 1/20 0.39
SCN9A Q15858 1/20 0.39
PPARG P37231 2/20 0.38
PPARD Q03181 2/20 0.38
PPARA Q07869 2/20 0.38
HIF1A Q16665 1/20 0.38
AKR1B1 P15121 1/20 0.38
FFAR4 Q5NUL3 1/20 0.37
CHRM4 P08173 2/20 0.37
GCK P35557 1/20 0.36
MAOB P27338 1/20 0.36
AOC3 Q16853 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3487706 0.90 PPARG (0.41) SLC1A3SLC1A2SLC1A1CARM1PRMT6
SCHEMBL3487565 0.90 HTR2A (0.46) CARM1PRMT6PPARGPPARDPPARA
SCHEMBL3487417 0.88 HTR2A (0.46) SOS1HIF1AAKR1B1
SCHEMBL3488032 0.88 SLC6A4 (0.45) SCN9APPARGPPARAHIF1AAKR1B1
SCHEMBL3488332 0.88 GCK (0.46) CARM1PRMT6SCN9APPARGPPARD
SCHEMBL3488269 0.86 EGLN1 (0.42) PPARGPPARDPPARAHIF1AFFAR4
SCHEMBL3487536 0.85 GCK (0.42) CARM1PRMT6PPARGHIF1AAKR1B1
SCHEMBL3487252 0.84 GCK (0.41) CARM1PRMT6PPARGPPARDPPARA
SCHEMBL3488377 0.84 HIF1A (0.43) CARM1PRMT6SCN9APPARGHIF1A
SCHEMBL3488176 0.83 TEAD4 (0.46) FFAR4GCK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2138484-B1 FUSED BICYCLIC HETEROARYL DERIVATIVES DAIICHI SANKYO CO LTD (JP) 2015-08-26 EP disclosed
US-20100048564-A1 FUSED BICYCLIC HETEROARYL DERIVATIVE DAIICHI SANKYO COMPANY, LIMITED (JP) 2010-02-25 US disclosed
EP-2138484-A1 FUSED BICYCLIC HETEROARYL DERIVATIVES Daiichi Sankyo Company, Limited (JP) 2009-12-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100048564-A1 FUSED BICYCLIC HETEROARYL DERIVATIVE PPARG, GPR119, PPARA SLC1A3 1739/4885SLC1A2 2114/4885SLC1A1 1316/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.